ConM SOSIP

ConM SOSIP is a stabilized, native-like trimeric HIV-1 envelope glycoprotein (Env) immunogen designed using a consensus sequence of all HIV-1 group M isolates. The "SOSIP" modification refers to engineered disulfide bonds and point mutations that stabilize the Env trimer in its prefusion conformation, closely mimicking the structure of the native viral spike. The most advanced version in clinical development is ConM SOSIP.v7. ConM SOSIP displays epitopes recognized by broadly neutralizing antibodies (bNAbs) and their precursors while minimizing rare isolate-specific antigenic residues[1][6]. It elicits strong autologous neutralizing antibody responses in animal models and has entered phase 1 clinical trials as an experimental vaccine for HIV-1 prevention[8][10]. Immunogenicity studies show that it predominantly induces antibodies targeting the V1V2V3 regions at or near the trimer apex[6].

Other names

ConM SOSIP.v7 gp140 trimerConM SOSIP.v7 HIV-1 Env trimerConsensus M SOSIP.v7